Edition:
United Kingdom

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

52.85USD
12 Nov 2018
Change (% chg)

$-0.54 (-1.01%)
Prev Close
$53.39
Open
$53.36
Day's High
$53.50
Day's Low
$52.70
Volume
1,658,550
Avg. Vol
1,744,193
52-wk High
$70.04
52-wk Low
$46.95

Summary

Name Age Since Current Position

Giovanni Caforio

53 2017 Chairman of the Board, Chief Executive Officer

Charles Bancroft

58 2016 Chief Financial Officer, Executive Vice President - Global Business Operations

Ann Judge

52 2016 Chief Human Resource Officer, Senior Vice President

Thomas Lynch

57 2017 Chief Scientific Officer, Executive Vice President

Sandra Leung

57 2015 Executive Vice President, General Counsel

Christopher Boerner

47 2018 Executive Vice President and Chief Commercial Officer

Paul von Autenried

56 2016 Chief Information Officer, Senior Vice President

Karen Santiago

47 2018 Senior Vice President, Controller

John Elicker

58 2017 Senior Vice President - Corporate Affairs and Investor Relations

Louis Schmukler

62 2017 Senior Vice President, President - Global Product Development and Supply

Vicki Sato

69 2017 Lead Independent Director

Peter Arduini

53 2016 Independent Director

Robert Bertolini

56 2017 Independent Director

Matthew Emmens

66 2017 Independent Director

Michael Grobstein

75 2007 Independent Director

Alan Lacy

64 2008 Independent Director

Dinesh Paliwal

60 2013 Independent Director

Theodore Samuels

63 2017 Independent Director

Gerald Storch

61 2012 Independent Director

Karen Vousden

60 2018 Independent Director

Biographies

Name Description

Giovanni Caforio

Dr. Giovanni Caforio M.D., serves as Chairman of the Board, Chief Executive Officer of the Company since May 02 2017. Dr. Caforio has been our Chief Executive Officer since May 2015 and our Chairman since May 2017. He was our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. Dr. Caforio held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization. Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton, Business Roundtable, CEO Roundtable on Cancer and the Pharmaceutical Research and Manufacturers of America. With over 26 years of pharmaceutical industry experience, including more than 16 years at the company, Dr. Caforio has overseen the creation of a fully integrated worldwide commercial organization as part of our evolution into a diversified specialty biopharmaceutical company.

Charles Bancroft

Mr. Charles A. Bancroft serves as Chief Financial Officer, Executive Vice President - Global Business Operations of the Company. He served as 2011 to 2016 - Chief Financial Officer and Executive Vice President, Global Services. He joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.

Ann Judge

Ms. Ann Powell Judge serves as Chief Human Resource Officer, Senior Vice President of the Company. She served from 2009 to 2013 – Chief Human Resources Officer, Shire Pharmaceuticals, 2013 to 2016 – Senior Vice President, Global Human Resources, 2016 to present – Senior Vice President, Chief Human Resources Officer.

Thomas Lynch

Dr. Thomas J. Lynch, Jr. M.D. Ph.D., is Chief Scientific Officer, Executive Vice President of the Company since March 16, 2017. He has served as the Chairman and Chief Executive Officer of Massachusetts General Physicians Organization since July 2015. He has also served as a member of the Board of Directors of Massachusetts General Hospital since 2015. From 2009 to 2015, he was the Director of Yale Cancer Center and the Richard and Jonathan Sackler Professor of Internal Medicine, Yale Cancer Center, Yale School of Medicine. He also served as the Physician-in-Chief of Smilow Cancer Hospital, Yale-New Haven. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

Sandra Leung

Ms. Sandra Leung serves as Executive Vice President, General Counsel of the Company. From 2007 to 2014 – General Counsel and Corporate Secretary, 2014 to 2015 – Executive Vice President, General Counsel and Corporate Secretary, 2015 to present – Executive Vice President, General Counsel.

Christopher Boerner

Dr. Christopher Boerner, Ph.D. is Executive Vice President and Chief Commercial Officer of the Company. He most recently served as the Company’s head of international markets from October 2017 to August 2018. He joined the Company in February 2015 as head of the U.S. commercial organization and served in that role until October 2017. Prior to joining the Company, he was with Seattle Genetics, Inc., where he served as executive vice president of commercial from 2014 to 2015 and senior vice president of commercial from 2012 to 2014. Before joining Seattle Genetics, Mr. Boerner was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin, director of Avastin franchise strategy and associate director of oncology market development.

Paul von Autenried

Mr. Paul von Autenried is Chief Information Officer, Senior Vice President of the Company. From 2011 to 2012 – Senior Vice President and Chief Information Officer; 2012 to 2016 – Senior Vice President, Enterprise Services and Chief Information Officer; 2016 to present – Senior Vice President, Chief Information Officer.

Karen Santiago

Ms. Karen Santiago is appointed as Senior Vice President, Controller of the company effective February 15, 2018. She joined Bristol-Myers Squibb Company in 2003 and has served in multiple roles of increasing responsibility. Most recently, from 2012 to 2015 she served as Vice President, Finance for Global Manufacturing and Supply, from 2015 to 2016 as Vice President, Finance for US and Puerto Rico Commercial and since 2016 she has been Vice President, Lead for Enabling Functions and Finance Transformation. Ms. Santiago has an M.B.A. in Finance and a B.S. in Accounting and is a Certified Public Accountant.

John Elicker

Mr. John E. Elicker is Senior Vice President - Corporate Affairs and Investor Relations of the Company. From 2000 to 2002 – Senior Director, Investor Relations, 2002 to 2010 –Vice President, Investor Relations, 2010 to 2012 – Senior Vice President, Investor Relations., 2012 to 2017 – Senior Vice President, Public Affairs and Investor Relations.

Louis Schmukler

Mr. Louis S. Schmukler serves as Senior Vice President, President - Global Product Development and Supply of the Company. From 2007 to 2009, he was Senior Vice President, Pharmaceutical Operating Unit, Wyeth and from 2009 to 2011 – Senior Vice President, Specialty/Biotechnology Operating Unit, Pfizer., 2011 to 2017 – President, Global Product Development and Supply.

Vicki Sato

Dr. Vicki L. Sato, Ph.D., serves as Lead Independent Director of Bristol-Myers Squibb Company. Dr. Sato serves as Chairman of the Board of Directors of Denali Therapeutics, Inc. She previously served as a professor of management practice at the Harvard Business School from July 2005 to June 2017. From July 2005 to October 2014 she served as professor of the practice of molecular and cell biology at Harvard University. In 2005, Dr. Sato retired as President of Vertex Pharmaceuticals Incorporated, a global biotechnology company, where she was responsible for research and development, business and corporate development, commercial operations, legal and finance. Dr. Sato also served as Chief Scientific Officer, Senior Vice President of Research and Development and Chair of the Scientific Advisory Board at Vertex before being named President in 2000. She serves as Chairman of VIR Biotechnology, Inc. and on the Board of Directors of the Peer Health Exchange, Inc. She serves as Co-Chair on the Task Force on Science and Engineering at Harvard University and Co-Chair on the Advisory Council of LifeSci NYC. Dr. Sato's extensive and distinctive experience in business, academia and science over more than 31 years brings to the Board a valuable perspective on the biotech industry.

Peter Arduini

Mr. Peter J. Arduini serves as Independent Director of the Company effective April 1, 2016. Mr. Arduini has been President and Chief Executive Officer of Integra LifeSciences Holdings Corporation, a global medical technology company, since January 2012 and currently serves as a member of Integra's Board of Directors. He served as President and Chief Operating Officer of Integra from November 2010 to January 2012. Before joining Integra, Mr. Arduini was Corporate Vice President and President of Medication Delivery, Baxter Healthcare, from 2005 to 2010. Prior to joining Baxter, he worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association), the Board of Directors of MDIC (the Medical Device Innovation Consortium), and the Board of Directors of the National Italian American Foundation. Mr. Arduini also serves on the Board of Trustees of Susquehanna University. With over 25 years in the healthcare industry, Mr. Arduini brings to the Board extensive leadership, business and operational experience, particularly with respect to manufacturing and sales of medical technology and devices.

Robert Bertolini

Mr. Robert J. Bertolini , CPA., is Independent Director of the Company. Mr. Bertolini served as President and Chief Financial Officer of Bausch & Lomb Incorporated from February 2013 until August 2013 (until its acquisition by Valeant Pharmaceuticals). Previously, Mr. Bertolini served as Executive Vice President and Chief Financial Officer at Schering-Plough Corp. from November 2003 until November 2009 (through its merger with Merck & Co.) with responsibility for tax, accounting and financial asset management. Prior to joining Schering-Plough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, ultimately leading its global pharmaceutical industry practice. In addition, as a former chief financial officer who also has over 20 years' experience at a major auditing firm, Mr. Bertolini has extensive knowledge and background related to accounting and financial reporting rules and regulations as well as the evaluation of financial results, internal controls and business processes and this positions him well to serve as Chair of our Audit Committee and a member of our Committee on Directors and Corporate Governance.

Matthew Emmens

Mr. Matthew W. Emmens is Independent Director of the Company. Mr. Emmens served as Chief Executive Officer of Shire PLC from 2003 to 2008 and Chairman of the Board from 2008 to 2014. He also served as a Director of Vertex Pharmaceuticals Incorporated from 2004 to 2009, Chairman, President and Chief Executive Officer from 2009 to 2012 and Director from 2012 to 2013. Mr. Emmens served as President, Worldwide Pharmaceuticals of Merck KGaA from 1999 to 2003, as Chief Executive Officer, Commercial Operations of Astra Merck Inc. from 1992 to 1999 and in Sales, Marketing and Administration positions for Merck & Co, Inc. from 1974 to 1991. With over 40 years in the biopharmaceutical industry, Mr. Emmens brings to the Board significant expertise in management, business development, business and operations, particularly with respect to strategy and team effectiveness.

Michael Grobstein

Mr. Michael Grobstein is Independent Director of Bristol-Myers Squibb Company. Mr. Grobstein is a retired Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. He worked with Ernst & Young from 1964 to 1998, and was admitted as a partner in 1975. Mr. Grobstein served as a Vice Chairman-International Operations from 1993 to 1998, as Vice Chairman-Planning, Marketing and Industry Services from 1987 to 1993, and Vice Chairman-Accounting and Auditing Services from 1984 to 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc. With over 30 years of experience at a major auditing firm, and 20 years as a director of public companies with global operations, Mr. Grobstein has extensive knowledge and background relating to accounting and financial reporting rules and regulations as well as the evaluation of financial results, internal controls and business processes.

Alan Lacy

Mr. Alan J. Lacy is Independent Director of Bristol-Myers Squibb Company. Mr. Lacy served as the Non-Executive Chairman of Dave & Buster's Entertainment Inc. from 2014 to 2017. He served as the Chairman and Chief Executive Officer of Sears, Roebuck and Co. and the Vice Chairman and Chief Executive Officer of its successor, Sears Holdings Corporation, from 2000 to 2005. Mr. Lacy also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. More recently, Mr. Lacy served as Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, from 2007 to 2014. He is a Trustee of Fidelity Funds and the California Chapter of The Nature Conservancy. Mr. Lacy is a Director of the Center for Advanced Study in the Behavioral Sciences at Stanford University.

Dinesh Paliwal

Mr. Dinesh C. Paliwal serves as Independent Director of Bristol-Myers Squibb Company. Mr. Paliwal has served as President and Chief Executive Officer of Harman International, the connected technologies company for automotive, consumer and enterprise markets, since 2007. Mr. Paliwal also served as Chairman of the Harman Board of Directors from July 2008 to March 2017 until its acquisition by Samsung Electronics Co., Ltd. Today Harman operates as a wholly-owned subsidiary of Samsung. Prior to joining Harman, Mr. Paliwal served as a member of the Group Executive Committee of ABB Ltd., a provider of industrial automation, power transmission systems and services, from January 2001 until June 2007. He also served as President of Global Markets and Technology of ABB Ltd. from January 2006 until June 2007, as Chairman and Chief Executive Officer of ABB North America from January 2004 until June 2007, and as President and Chief Executive Officer of ABB Automation Technologies Division from October 2002 to December 2005. Mr. Paliwal is a member of the CEO Business Roundtable. He also serves on the Boards of Directors of the Business Advisory Council of Farmer School of Business, Miami University of Ohio and the U.S. India Business Council.

Theodore Samuels

Mr. Theodore R. Samuels II, is Independent Director of the Company. Mr. Samuels served with Capital Group Companies from 1981 to 2016. He was President of the Capital Guardian Trust Company from 2010 to 2016 and was the Capital Group representative for Focusing Capital on the Long Term from 2014 to 2015. Mr. Samuels was a portfolio manager from 1990 to 2016, and while at Capital Group served on numerous management and investment committees. He also served as a board member of Capital Group Foundation and as Chair of Capital Group Foundation Investment Committee and the Capital International (North America) Proxy Committee. Mr. Samuels served on the Capital Group Finance Committee from 2013-2016 and previously served on the Capital Group Board and the Capital Group Audit Committee. He also serves as Co-chair of Tuft's President's Council and the Harvard West Cost Council. Mr. Samuels is a Director of Children's Hospital Los Angeles, where he served as Co-chair of the Board of Trustees from 2012 to 2015 and is also a trustee of the Pasadena City College Foundation. With over 35 years in the financial industry, Mr. Samuels brings to the Board extensive business and operational experience, particularly with respect to economics and investment decision-making.

Gerald Storch

Mr. Gerald Leonard Storch is Independent Director of Bristol-Myers Squibb Company. Mr. Storch has served as Chief Executive Officer of Storch Advisors since November 2017, a position he had also held from November 2013 to January 2015. He served as Chief Executive Officer of Hudson's Bay Company from January 2015 to November 2017, a leading owner and operator of department stores, including Saks Fifth Avenue, Lord & Taylor, Hudson's Bay Department Stores, Home Outfitters, Saks OFF 5th, Kaufhof, Inno and the e-commerce business Gilt. He also served as Chairman of Toys"R"Us, Inc. from February 2006 to November 2013 and Chief Executive Officer of Toys"R"Us from February 2006 to May 2013. Prior to joining Toys"R"Us, Mr. Storch served as Vice Chairman of Target Corporation. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company. He is a director of Fanatics, Inc. A retail veteran with more than 20 years of experience, Mr. Storch provides the Board with valuable business, leadership and management insight, including expertise leading an organization with global operations, giving him a keen understanding of the issues facing a multi-national business.

Karen Vousden

Dr. Karen H. Vousden, Ph.D., serves as Independent Director of the Company effective January 1, 2018. Dr. Vousden has been a Senior Group Leader at the Francis Crick Institute in London since February 2017 and Chief Scientist of Cancer Research UK since July 2016. From 2002 to 2016 she served as the Director of the Cancer Research-UK (CRUK) Beatson Institute in Glasgow, prior to which she held leadership roles at the National Cancer Institute in Maryland from 1995 to 2002. She serves as a member of the Science Advisory Boards of Centro Nacional de Investigaciones Oncologicas, Grail, Inc., Ludwig Institute for Cancer Research, PMV Pharma, Raze Therapeutics and Swiss Institute for Experimental Cancer Research. Dr. Vousden is a Council member of the European Molecular Biology Organization. She is also a Fellow of the Royal Society. With over 30 years of experience leading ground-breaking cancer research, Dr. Vousden brings to the Board important perspective and knowledge on a variety of healthcare related issues, including the inherent challenges facing our R&D organization in discovering and developing new medicines.